SerpinPC

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 24/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hemophilia a

Conditions

Hemophilia a, Hemophilia B

Trial Timeline

Jul 6, 2023 → Feb 28, 2025

NCT ID

NCT05789524

About SerpinPC

SerpinPC is a phase 2 stage product being developed by Centessa Pharmaceuticals for Hemophilia a. The current trial status is terminated. This product is registered under clinical trial identifier NCT05789524. Target conditions include Hemophilia a, Hemophilia B.

What happened to similar drugs?

20 of 20 similar drugs in Hemophilia a were approved

Approved (20) Terminated (3) Active (0)

✅EmicizumabRocheApproved

✅BenefixPfizerApproved

✅Nonacog alfaPfizerApproved

✅moroctocog alfa (AF-CC) (ReFacto AF)PfizerApproved

✅Recombinant Factor IX CoagulationPfizerApproved

✅Moroctocog alfa(AF-CC)PfizerApproved

✅Factor IX recoveryPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06568302	Phase 3	Terminated	Jul 11, 2024	Jan 29, 2025	Hemophilia a
NCT05789537	Phase 2	Terminated	Jul 28, 2023	Feb 24, 2025	Hemophilia B with Inhibitor
NCT05789524	Phase 2	Terminated	Jul 6, 2023	Feb 28, 2025	Hemophilia a

Competing Products

20 competing products in Hemophilia a

See all competitors

Product	Company	Stage	Hype Score
Emicizumab	Chugai Pharmaceutical	Phase 3	40
Emicizumab	Chugai Pharmaceutical	Phase 3	40
Emicizumab + rFVIIa + aPCC	Chugai Pharmaceutical	Phase 3	40
Human Coagulation Factor VIII	Chugai Pharmaceutical	Phase 3	47
Emicizumab	Chugai Pharmaceutical	Phase 3	47
Emicizumab + Factor VIII (FVIII)	Chugai Pharmaceutical	Phase 3	40
Emicizumab	Roche	Phase 3	40
HEMLIBRA	Johnson & Johnson	Pre-clinical	26
Emicizumab	Roche	Phase 3	40
Emicizumab	Roche	Approved	47
Emicizumab	Roche	Phase 3	44
SPK-8011QQ	Roche	Phase 1/2	39
NXT007	Roche	Phase 1/2	39
Emicizumab Injection	Roche	Phase 2	35
Bypassing Agents + FVIII Replacement	Roche	Pre-clinical	26
PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086	Pfizer	Phase 2	35
Nonacog Alfa (Genetical Recombination)	Pfizer	Pre-clinical	26
Refacto AF	Pfizer	Pre-clinical	18
PF-06838435/ fidanacogene elaparvovec	Pfizer	Phase 3	44
ReFacto AF	Pfizer	Phase 3	40